To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
OE Original Cover

Treatment Options for COVID-19: Evidence Review for Promising Candidates

Share
Cite This
+ Favorites
Share
Cite This
+ Favorites
June 28, 2021

Treatment Options for COVID-19: Evidence Review for Promising Candidates

Vol: 4| Issue: 6| Number:4| ISSN#: 2563-559X

Authored By: Meng Zhu, Mohit Bhandari On Behalf of OrthoEvidence

Banner Image
Since the beginning of the COVID-19 pandemic, the government of the United States (US) has invested over 19 billion US dollars in 7 private pharmaceutical manufacturers in order to promote the development and production of effective vaccines against SARS-CoV-2 infection (US Congressional Budget Office). So far, vaccines from 3 of the 7 pharmaceutical manufacturers, including Pfizer/BioNTech, Moderna, and Janssen, have been granted the emergency use authorization (EUA) by the US Food and Drug Administration (FDA). These vaccines, along with those used outside the US (e.g., the AstraZeneca vaccine), have prevented hundreds of thousands of SARS-CoV-2 infections all over the world. On top of the progress made for COVID-19 vaccines, the US government recently turned their eyes to antiviral medicines against SARS-CoV-2. On June 17th, 2021, the US Department of Health and Human Services (HHS) announced....
OE OriginalPreview Image

SHARE THIS OE ORIGINAL

Loading...

Join the Conversation

Please Login or Join to leave comments.